Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of “Buy” from Analysts
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received an average rating of “Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month […]
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) have received an average rating of “Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month […]
